Mefloquine: A Review of its Antimalarial Activity, Pharmacokinetic Properties and Therapeutic Efficacy

Drugs

Volumn 45, Issue 3, 1993, Pages 430-475

  Palmer, Katharine J ^a   Holliday, Stephen M ^a   Brogden, Rex N ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMALARIAL AGENT; ARTEMISININ DERIVATIVE; CHLOROQUINE; HALOFANTRINE; MEFLOQUINE; PRIMAQUINE; PYRIMETHAMINE; QUININE; SULFADOXINE; TETRACYCLINE;

ABDOMINAL PAIN; AFFECTIVE NEUROSIS; AGRANULOCYTOSIS; ANTIMALARIAL ACTIVITY; BRADYCARDIA; DIARRHEA; HEADACHE; HEARING DISORDER; HEMOLYTIC ANEMIA; HUMAN; INSOMNIA; LEUKOPENIA; LYMPHADENOPATHY; MALARIA; MENTAL DISEASE; MULTIDRUG RESISTANCE; NAUSEA; NEUROPSYCHIATRY; NEUROSIS; PLASMODIUM FALCIPARUM; PLASMODIUM VIVAX; PRIORITY JOURNAL; PRURITUS; RASH; REVIEW; SEIZURE; SINUS ARRHYTHMIA; TERATOGENESIS; THROMBOCYTOPENIA; VERTIGO; VISUAL DISORDER; VOMITING;

ANIMAL; HUMAN; MALARIA, FALCIPARUM; MEFLOQUINE;

EID: 0027403103     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/00003495-199345030-00009     Document Type: Article

References (257)

1. Mefloquine prophylaxis and neurotoxicity
2. A comparative clinical trial of mefloquine and chloroquine in the treatment of vivax malaria
3. A comparative study of gastrointestinal infections in United States soldiers receiving doxycycline or mefloquine for malaria prophylaxis
4. Mefloquine prophylaxis. Correspondence
5. Clinical trial of Fansimef in Indian patients of P. falciparum malaria
6. Genetic diversity of Plasmodium falciparum in a village in eastern Sudan. 2. Drug resistance, molecular karyotypes and the mdr 1 genotype of recent isolates
7. Selection for high-level chloroquine resistance results in deampli-fication of the pfmdrl gene and increased sensitivity to mefloquine in Plasmodium falciparum
8. In vitro activity of the enantiomers of mefloquine, halofantrine and enpiroline against Plasmodium falciparum
9. In vitro activity of halofantrine and its relationship to other standard antimalarial drugs against African isolates and clones of Plasmodium falciparum
10. Chloroquine and proguanil prophylaxis in travellers to Kenya. Correspondence
11. Sensitivity to mefloquine in vitro of chloroquine-re-sistant Plasmodium falciparum from Vanuatu
12. Mefloquine prophylaxis: an overview of spontaneous reports of severe psychiatric reactions and convulsions
13. Exacerbation of epilepsy during prophylactic treatment with mefloquine
14. Acute psychosis following mefloquine prophylaxis. Correspondence
15. Fansidar resistant falciparum malaria acquired in South East Asia
16. Antimalarial Drugs
17. Prospective double-blind trial of two different doses of mefloquine plus pyrimethamine-sul-fadoxine compared with pyrimethamine-sulfadoxine alone in the treatment of falciparum malaria
18. Mefloquine kinetics in cured and recrudescent patients with acute falciparum malaria and in healthy volunteers
19. Comparison of mefloquine, chloroquine plus pyrimethamine-sulfadoxine (Fansidar®), and chloroquine as malarial prophylaxis in Eastern Thailand
20. Type II mefloquine resistance in Thailand. Correspondence
21. Patterns of in vitro resistance to chloroquine, quinine, and mefloquine of Plasmodium falciparum in Cameroon, 1985–1986
22. Mefloquine-resistant malaria induced by inappropriate quinine regimens? Correspondence
23. Emergence of mefloquine-resistant malaria in Africa without drug pressure. Correspondence
24. Multi-drug resistant falciparum malaria in Cameroon in 1987–1988 II. Mefloquine resistance confirmed in vivo and in vitro and its correlation with quinine resistance
25. Low sensitivity to chloroquine and quinine of Plasmodium falciparum isolates from Guinea in March 1986
26. Failure of anti-malaria mefloquine prophylaxis in West Africa
27. Mefloquine sulfadoxine pyrimethamine (MSP) combination delays in vitro emergence of mefloquine resistance in multiple drug resistant Plasmodium falciparum
28. Halofantrine. A Review of its antimalarial activity, pharmacokinetic properties and therapeutic potential
29. The current status of drug resistance in malaria
30. Fansimef for prophylaxis of malaria: a double-blind randomised placebo controlled trial
31. Concurrent chloroquine and Fansidar resistance of Plasmodium falciparum: an imported case from Gabon
32. Mefloquine resistance of falciparum malaria from Tanzania enhanced by treatment. Correspondence
33. Acute depressive symptoms after mefloquine treatment. Correspondence
34. Antimalarial aminoalcohol alternatives to mefloquine
35. Unexpected trend in chemosensitivity of Plasmodium falciparum in Brazzaville Congo. Correspondence
36. Optical isomers of aryl-2-piperidylmethanol antimalarial agents. Preparation, optical purity, and absolute stereochemistry
37. Revised dosing regimen for malaria prophylaxis with mefloquine
38. The effect of artemisinin combined with standard antimalarials against chloroquine-sensitive and chloroquine-resistant strains of Plasmodium falciparum in vitro
39. The effect of combinations of qinghaosu (artemisinin) with standard antimalarial drugs in the suppressive treatment of malaria in mice
40. The antimalarial drug mefloquine binds to membrane phospholipids
41. Smear-negative cerebral malaria due to mefloquine-resistant Plasmodium falciparum acquired in the Amazon. Correspondence
42. In vitro and clinical correlates of mefloquine resistance of Plasmodium falciparum in eastern Thailand
43. In vitro activity of pyronaridine against field isolates and reference clones of Plasmodium falciparum
44. In vitro mefloquine resistance of Plasmodium falciparum isolated from the Burmese border region of Thailand
45. Sensitivity in vitro of Plasmodium falciparum to chloroquine and mefloquine in two regions of Benin
46. A phase-III clinical trial of mefloquine in children with chloroquine-resistant falciparum malaria in Thailand
47. Suppressive activity of mefloquine in sporozoite-induced human malaria
48. Effect of mefloquine and artemisinin on the sporogonic cycle of Plasmodium berghei ANKA in Anopheles stephensi mosquitoes
49. Mefloquine failure in a case of falciparum malaria induced with a multidrug-resistant isolate in a non-immune subject
50. Mefloquine, a clinically useful quinolinemethanol antimalarial which does not significantly bind to DNA. Correspondence
51. Mefloquine clinical trials — therapeutical experience with mefloquine alone and combination (MSP) in Brazilian male subjects with falciparum malaria
52. Note on the in vitro activity of various antimalarial drugs (chloroquine, amodiaquine, quinine and mefloquine) against, 32 Plasmodium falciparum isolates from French Guiana
53. Falciparum malarial after failure of mefloquine chemoprophylaxis in a traveller returning from Ivory Coast
54. Quantitative assessment of antimalarial activity in vitro by a semiauto-mated microdilution technique
55. Kinetics of a new antimalarial, mefloquine
56. Evaluation of Plasmodium falciparum response to chloroquine, quinine and mefloquine
57. Treatment of an acute case of Plasmodium malariae malaria with mefloquine
58. A clinical trial of mefloquine in the treatment of Plasmodium vivax malaria
59. A comparative trial of mefloquine and Fansidar in the treatment of falciparum malaria: failure of Fansidar
60. Single-dose therapy of falciparum malaria with mefloquine or pyrimethamine-sulfadoxine
61. Comparison of Ro 21-5998 (mefloquine) and Fansidar (pyrimethamine plus sulfadoxine) for the treatment of Plasmodium falciparum malaria in the Amazon
62. Serial studies on the evolution of drug resistance in malaria in an area of east Africa: findings from 1979 up to 1986
63. A comparative micro in vitro test of P. falciparum to mefloquine and chloroquine in Gadchiroli District, Maharashtra State
64. The response of Plasmodium falciparum to chloroquine and mefloquine in Bandar-Abbas and Minab areas, Hormozgan Province, southern Iran
65. In vitro response of Plasmodium falciparum to mefloquine in south-eastern Iran. Correspondence
66. Excretion of mefloquine in human breast milk
67. Synergism between arteether and mefloquine or quinine in a multidrug-resistant strain of Plasmodium falciparum in vitro
68. A double-blind trial of a fixed combination of mefloquine plus sulfa-doxine-pyrimethamine compared with sulfadoxine-pyrimeth-amine alone in symptomatic falciparum malaria
69. A double-blind clinical trial of a combination of mefloquine, sulfadoxine and pyrimethamine in symptomatic falciparum malaria
70. A doubleblind comparative clinical trial of mefloquine and chloroquine in symptomatic falciparum malaria
71. Comparison of the susceptibility of falciparum malaria to mefloquine-sulphadoxine-pyrimethamine and chloroquine in Nigeria
72. Mode of action of antimalarial drugs
73. Psychotic episode following mefloquine malaria prophylaxis — case report
74. Divided-dose kinetics of mefloquine in man
75. Mefloquine failure in child contracting falciparum malaria in West Africa. Correspondence
76. Cross-resistance between mefloquine and halofantrine. Correspondence
77. Severe malaria under mefloquine, in a woman returning from West Africa. Correspondence
78. Malaria in French Guyana: in vivo and in vitro drug sensitivity and therapeutic implications. Abstract no. S9 D20
79. Stage specific actions of antimalarial drugs on Plasmodium falciparum in culture
80. Drug resistant P. falciparum in Madras (Tamil Nadu) and district Jabalpur (Madhya Pradesh)
81. The first report of Plasmodium falciparum resistant to chloroquine plus sulphadoxine/pyri-methamine in Rwanda
82. Determination of the enantiomers of mefloquine in plasma and whole blood using a coupled achiral-chiral high-performance liquid Chromatographie system
83. Alkalinization of the food vacuole of malaria parasites by quinoline drugs and alkylamines is not correlated with their antimalarial activity
84. Antiprotozoal drugs
85. Double-blind dose finding study of mefloquine-sulfadoxine-pyrimethamine in children with acute falciparum malaria
86. Comparison of the activity in vitro of mefloquine and two metabolites against Plasmodium falciparum
87. Quinine resistant falciparum malaria treated with mefloquine
88. Trials of mefloquine in vivax and of mefloquine plus ‘Fansidar’ in falciparum malaria
89. Mefloquine, sulfadoxine, and pyrimethamine in the treatment of symptomatic falciparum malaria: a double-blind trial for determining the most effective dose
90. A phase II clinical trial of mefloquine in patients with chloroquine-resistant falciparum malaria in Thailand
91. A clinical trial of mefloquine on multi-resistant falciparum malaria in pregnant women in Thailand. Abstract no. S4 C31
92. Susceptibility of Plasmodium falciparum strains to mefloquine in an urban area in Senegal
93. Agranulocytosis during treatment with mefloquine. Correspondence
94. Prevention of malaria
95. RII and RIII type resistance of Plasmodium falciparum to combination of mefloquine and sulfadoxine/pyri-methamine in Indonesia
96. In vitro assessment of sensitivity of Plasmodium falciparum to chloroquine and mefloquine in Ghana
97. Breakdown of mefloquine prophylaxis in Central Africa. Correspondence
98. Lysosomes, pH and the anti-malarial action of chloroquine
99. An ultrastructural study of the effects of mefloquine on malaria parasites
100. Use of mefloquine in epileptic patients. Correspondence
101. Antimalarial activity of mefloquine and qinghaosu
102. Mefloquine disposition in normals and in patients with severe Plasmodium falciparum malaria
103. The effectiveness of chemoprophylaxis against malaria for non-immune migrant workers in eastern Thailand
104. A comparison of the pharmacokinetics of mefloquine in healthy Thai volunteers and in Thai patients with falciparum malaria
105. The pharmacokinetics of mefloquine when given alone or in combination with sulphadoxine and pyrimethamine in Thai male and female subjects
106. Effect of oral contraceptive steroids on the clinical course of malaria infection and on the pharmacokinetics of mefloquine in Thai women
107. Pharmacokinetic of mefloquine in the presence of primaquine
108. Plasma and whole blood mefloquine concentrations during treatment of chloroquine-resistant falciparum malaria with the combination mefloquine-sulphadoxine-pyrimethamine
109. Pharmacokinetics of prophylactic mefloquine
110. Pharmacokinetics and pharmacodynamics of mefloquine in Thai patients with acute falciparum malaria
111. Pharmacokinetics of prophylactic mefloquine in Thai healthy volunteers
112. Comparison of oral artemether and mefloquine in acute uncomplicated falciparum malaria
113. Pharmacokinetics of mefloquine in treatment failure
114. Clinical pharmacokinetics of mefloquine
115. Crystal structure and molecular structure of mefloquine methylsulfonate monohydrate: implications for a malaria receptor
116. Absolute stereochemistry of the enantiomers of mefloquine hydrochloride in relation to their antimalarial activity
117. Micro in vitro assessment of Plasmodium falciparum sensitivity to chloroquine and mefloquine in Gujarat
118. Two cases of mefloquine resistant malaria in Thailand
119. Chemotherapeutic studies with mefloquine and selection of a mefloquine resistant strain of Plasmodium berghei
120. Comparative trial on the response of Plasmodium falciparum to halofantrine and mefloquine in Trat Province, Eastern Thailand
121. In vitro response of Plasmodium falciparum to chloroquine and mefloquine in Southeast Madagascar
122. Low resistance of Plasmodium falciparum to mefloquine in Tanga region, Tanzania
123. In-vivo susceptibility of Plasmodium falciparum to chloroquine in pregnant and non-pregnant women and in-vi-tro response of P. falciparum to chloroquine and mefloquine in Madang Province, Papua New Guinea
124. The relationship between the in vitro response of Plasmodium falciparum to chloroquine, quinine and mefloquine
125. Tolerability of long-term malaria prophylaxis with the combination mefloquine + sulfadoxine + pyrimethamine (Fansimef®): results of a double blind field trail versus chloroquine un Nigeria
126. Quinine-resistant malaria. Correspondence
127. In vitro drug sensitivity of Plasmodium falciparum in Acre, Brazil
128. Antimalarials increase vesicle pH in Plasmodium falciparum
129. Plasmodium falciparum: mefloquine resistance produced in vitro
130. Effect of mefloquine on electrocardiographic changes in uncomplicated falciparum malaria patients
131. Susceptibility of Plasmodium falciparum to mefloquine in an urban area in Senegal
132. Chloroquine- resistant Plasmodium falciparum with reduced sensitivity in vitro to mefloquine and quinine in Zaria, Northern Nigeria
133. The in vitro response of Plasmodium falciparum to mefloquine at Lubwe and Kalene in Zambia
134. Effectiveness and tolerance of long-term malaria prophylaxis with mefloquine
135. Treatment of patients with recrudescent falciparum malaria with a sequential combination of artesunate and mefloquine
136. Randomised trial of artesunate and mefloquine alone and in sequence for acute uncomplicated falciparum malaria
137. High rate of Plasmodium vivax relapse following treatment of falciparum malaria in Thailand
138. Studies of mefloquine bioavailability and kinetics using a stable isotope technique: a comparison of Thai patients with falciparum malaria and healthy Caucasian volunteers
139. Mefloquine for multidrug-resistant malaria. Correspondence
140. Malaria
141. Treatment of Plasmodium falciparum malaria with mefloquine alone or in combination with IV quinine at the Department of Communicable and Tropical Diseases, Rigshospitalet, Copenhagen 1982–1988
142. Falciparum malaria resistant to quinine and pyrimethamine-sulfadoxine successfully treated with mefloquine
143. Single dose kinetic study of the triple combination mefloquine/sulphadoxine/pyrimethamine (Fansimef™) in healthy male volunteers
144. Reversal of chloroquine resistance in Plasmodium falciparum by verapamil
145. Susceptibility of Plasmodium falciparum strains to chloroquine and mefloquine in the Amazonas Federal Territory of Venezuela
146. Treatment of falciparum malaria with quinine and tetracycline or combined mefloquine/ sulfadoxine/pyrimeth-amine on the Thai-Kampuchean border
147. The inhibitory effect of a drug combination on the development of mefloquine resistance in Plasmodium berghei
148. Multiple-dose kinetic study of mefloquine in healthy male volunteers
149. Absorption kinetics of mefloquine in pregnant patients with chloroquine-resistant falciparum malaria. Abstract
150. Single dose pharmacokinetics of the anti-malarial mefloquine, sulphadoxine and pyrimethamine (MSP/Fansimef). Abstract no. 1321
151. Chemosuppression of malaria by the triple combination mefloquine/sulfadoxine/pyrimethamine: a field trial in an endemic area in Malaysia
152. Malaria on the Thai-Burmese border: treatment of 5192 patients with mefloquine-sulfadoxine- pyrimethamine
153. Mefloquine antimalarial prophylaxis in pregnancy: dose finding and pharmacokinetic study
154. Mefloquine pharmacokinetics and resistance in children with acute falciparum malaria
155. Mefloquine-resistant falciparum malaria on the Thai-Burmese border
156. A new probable case of cross resistance of P. falciparum to both mefloquine and halofantrine from Sierra Leone
157. Reduced in-vitro susceptibility to mefloquine in West African isolates of Plasmodium falciparum
158. Antimalarials. 7. Bis (trifluo-romethyl)-α- (2-piperidyl)-4-quinolinemethanols
159. Ultrastructure of Plasmodium falciparum ‘in vitro’. II. Morphological patterns of different quinolones effect
160. Paresthesias and mefloquine prophylaxis
161. Failure of mefloquine prophylaxis in East Africa. Correspondence
162. Treatment of malaria — 1990
163. Chemosuppressive field trials in Thailand IV. The suppression of Plasmodium falciparum and Plasmodium vivax parasitemias by mefloquine (WR 142,490, a 4-quinolineme-thanol)
164. The chemotherapy of rodent malaria, XXII. The value of drug-resistant strains of P. berghei in screening for blood schizontocidal activity
165. The chemotherapy of rodent malaria, XXVII. Studies on mefloquine (WR 142,490)
166. The chemotherapy of rodent malaria, XXVIII. The development of resistance to mefloquine (WR 142,490)
167. The chemotherapy of rodent malaria XXXV. Further studies on the retardation of drug resistance by the use of a triple combination of mefloquine, pyrimethamine and sulfadoxine in mice infected with P. berghei and ‘P. berghei NS’
168. The chemotherapy of rodent malaria. XLVI. Reversal of mefloquine resistance in rodent Plasmodium
169. The chemotherapy of rodent malaria XLII. Halofantrine and halofantrine resistance
170. Polymorphism of proteins in malaria parasites following mefloquine treatment
171. Double-blind study with different doses of mefloquine (Ro 21-5998) for the treatment of falciparum malaria in Brazil
172. Delay in emergence of mefloquine resistance in Plasmodium berghei by use of drug combinations
173. Failure of falciparum malaria prophylaxis by mefloquine in travellers from West Africa
174. Tolerance of mefloquine alone and in combination with sulfadoxine-pyrimetha-mine in the prophylaxis of malaria
175. Prophylactic activity of mefloquine hydro-chloride (WR 142490) in drug-resistant malaria
176. Failure of anti-malarial prophylaxis with mefloquine in Africa
177. The pharmacokinetics of mefloquine in man: lack of effect of mefloquine on antipyrine metabolism
178. Relapsing psychiatric syndrome induced by malarial prophylaxis with mefloquine: a case report
179. Mefloquine and an acute brain syndrome. Correspondence
180. Sensitivity of Plasmodium falciparum to mefloquine-sulphadoxine-pyrimethamine (Fansimef®) in vivo and to mefloquine alone in vitro in Nigeria
181. Antimalarial activities of various 4-quinolinemethanols with special attention to WR-142,490 (Mefloquine)
182. Urinary excretion of mefloquine and some of its metabolites in African volunteers at steady state
183. Single dose kinetics of mefloquine in man. Plasma levels of the unchanged drug and of one of its metabolites
184. Kinetic studies of mefloquine and of one of its metabolites, Ro 21-5104, in the dog and in man
185. Multiple-dose pharmacokinetics of the antimalarial drug Fansimef® (pyrimethamine.+ sulfadoxine + mefloquine) in healthy subjects
186. Halofantrine for the treatment of mefloquine chem-oprophylaxis failures in Plasmodium falciparum infections
187. Comparison of effects of pyronaridine, amodiaquine, mefloquine and qinghapsu on rodent malaria
188. Severe facial rash associated with mefloquine. Correspondence
189. The effect of mefloquine-artemether compared with quinine on patients with complicated falciparum malaria
190. Clinical studies on treatment of cerebral malaria with artemether and mefloquine
191. In vivo and in vitro efficacy of mefloquine in imported cases of Plasmodium falciparum malaria in France between 1985 and 1986
192. Reduced sensitivity of Plasmodium falciparum to mefloquine in West Africa. Correspondence
193. Seizures after mefloquine. Correspondence
194. Inhibition by chloroquine of a novel haem polymerase enzyme activity in malaria trophozoites
195. In vitro mefloquine resistant Plasmodium falciparum from the Philippines. Correspondence
196. Studies of resistance to chloroquine, quinine, amodiaquine and mefloquine among Philippine strains of Plasmodium falciparum
197. The relationship between the response of Plasmoduim falciparum malaria to mefloquine in African children and its sensitivity in vitro
198. Evaluation of the relative efficacy of various antimalarial drugs in Nigerian children under five years of age suffering from acute uncomplicated falciparum malaria
199. Clinical efficacy of mefloquine in children suffering from chloroquine-resistant Plasmodium falciparum malaria in Nigeria
200. Pruritus and antimalarial drugs in Africans. Correspondence
201. Plasmodium falciparum. Study of the drug sensitivity in the army
202. Mefloquine: safety and efficacy in European tourists visiting East Africa
203. The search for the new antimalarial drugs
204. Acute psychosis after mefloquine. Correspondence
205. Mefloquine plus sulfadoxine and pyrimethamine. Correspondence
206. Sensitivity to quinine and mefloquine of Plasmodium falciparum in Thailand
207. Mefloquine chemoprophylaxis of soldiers on the Thai-Cambodian border
208. Mefloquine-py-rimethamine-sulfadoxine combination delays emergence of mefloquine resistant Plasmodium falciparum in continuous culture
209. High-dose mefloquine in the treatment of multi-drug-resistant falciparum malaria
210. Susceptibility of Plasmodium falciparum to five drugs: an in vitro study of isolates mainly from Thailand
211. Variability in drug susceptibility amongst clones and isolates of Plasmodium falciparum
212. The effect of mefloquine-sulfadoxine-pyrimethamine vs quinine on patients with complicated falciparum malaria
213. Phase III double-blind comparative study of Fansimef® and Lariam® for the curative treatment of Plasmodium falciparum infections in Thailand
214. Single-dose treatment of falciparum malaria with mefloquine: field studies with different doses in semi-immune adults and children in Burma
215. Double-blind trial to find dose range using a fixed combination of mefloquine, sulfadoxine and pyrimethamine in falciparum malaria: a field study on adults in Burma
216. Falciparum malaria treated with a fixed combination of mefloquine, sulfadoxine and pyrimethamine: a field study in adults in Burma
217. Mefloquine (WR 142,490) in the treatment of human malaria
218. Mefloquine-induced Stevens-Johnson syndrome. Correspondence
219. Antimalarial interaction with ferriprotoporphyrin IX monomer and its relationship to activity of the blood schi-zontocides
220. The quinine-haemin interaction and its relationship to antimalarial activity
221. Susceptibility of Plasmodium falciparum in vitro to chloroquine, mefloquine, quinine and sulfadoxine/pyrimethamine in Somalia: relationships between the responses to the different drugs
222. Antimalarial drug susceptibility testing of Plasmodium falciparum in Thailand using a microdilution radioisotope method
223. Cloning and characterization of mefloquine-resistant Plasmodium falciparum from Thailand
224. Single-dose investigation of possible interactions between the components of the antimalarial combination Fansimef®
225. Neuropsychiatric side effects after the use of mefloquine
226. Genetic mapping of the chloroquine-resistance locus on Plasmodium falciparum chromosome 7
227. Clinical pharmacokinetics of antimalarial drugs
228. Combination treatment for falciparum prophylaxis. Correspondence
229. Emergence of multidrug-resistant Plasmodium falciparum in Thailand: in vitro tracking
230. Plasmodium species (malaria)